2006
Eosinophilic Cellulitislike Reaction to Subcutaneous Etanercept Injection
Abstract: Background: Injection site reactions are well recognized in patients treated with etanercept. Previous reports describe histologic findings of a cell-mediated T H 1 reaction, with CD8 ϩ T cells composing the majority of the dermal infiltrate. Observations: A pruritic, erythematous, edematous patch occurred on the right thigh of a 57-year-old white woman treated for rheumatoid arthritis within 12 to 24 hours after her second dose of subcutaneous etanercept. The patient had a similar reaction to adalimumab injec…
Search citation statements
Paper Sections
Select...
70
8
2
1
Citation Types
0
42
0
0
Year Published
2006
2025
Publication Types
Select...
62
16
1
Relationship
0
79
Authors
Journals
Cited by 79 publications
(42 citation statements)
References 7 publications
0
42
0
0
“…One study showed that certolizumab developed eosinophilia in up to 10 of 1000 patients (6). Similar cases have been reported regarding etanercept (7). It can be seen that most of the TNF-α inhibitors have the adverse effect of causing eosinophilia.…”
Section: Sirsmentioning
confidence: 52%
“…One study showed that certolizumab developed eosinophilia in up to 10 of 1000 patients (6). Similar cases have been reported regarding etanercept (7). It can be seen that most of the TNF-α inhibitors have the adverse effect of causing eosinophilia.…”
Section: Sirsmentioning
confidence: 52%
“…Previous reports in cases of ISR describe histologic findings of a cell‐mediated Th1 reaction, with CD8+ T cells composing the majority of the dermal infiltrate (4); however, histologic features of eosinophilic cellulitis as a response to etanercept suggest a Th2‐mediated phenomenon (5).…”
Section: Results Of Skin Testsmentioning
confidence: 99%
“…Although the mechanism of eosinophilia induction may differ across these three biologics, we speculate that the IgG/biologics immune complex-mediated complement activation and biologics-specific T cells-mediated reactions inducing a shift towards a T helper type 2 (Th2) immune response contributed to the patient's clinical symptoms. No previous reports have shown the presence of biologics-specific antibodies in RA patients with biologics-induced eosinophilia (7-19). …”
Section: Discussionmentioning
confidence: 96%
